Where does Theaprin Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Theaprin Pharmaceuticals, Inc. ranks #30,402 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Theaprin Pharmaceuticals, Inc. hold?

Theaprin Pharmaceuticals, Inc. holds 9 US utility patents granted between 2016 and 2025, spanning 9 technology areas.

What is Theaprin Pharmaceuticals, Inc.'s Innovation Score?

Theaprin Pharmaceuticals, Inc. has an Innovation Score of 23.8 out of 100 (13th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Theaprin Pharmaceuticals, Inc. focus on?

Theaprin Pharmaceuticals, Inc.'s top technology area is C07C (Acyclic OR Carbocyclic Compounds) with 9 patents, ranking #496 of 2,691 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Theaprin Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Theaprin Pharmaceuticals, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Theaprin Pharmaceuticals, Inc.'s patents?

Theaprin Pharmaceuticals, Inc.'s patents average 8.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Theaprin Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Theaprin Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 9 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Theaprin ranks #30,402 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 9 technology areas.

#30,402
of 49,997 US assignees by volume: 13th percentile
by Innovation Score (23.8/100): 8.8
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30402 · US Corporation #30,402 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #30,402/49,997
PHOTO-FINISH THE Lundquist…
CPC-NARROW C07C · 9 areas
INNOV-THIN 23.8/100
CLAIMS-PAR 8.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: THE Lundquist Institute FOR Biomedical Innovation AT Harbor-ucla Medical Center (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Theaprin’s 23.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (33%) Velocity 0.0 pts (0%) Breadth 10.6 pts (44%) Claim depth 5.3 pts (22%)

Qualcomm Incorporated · highest

85
Theaprin Pharmaceuti… · this assignee

24
3D Lighting… · lowest

7

What this shows Theaprin's Innovation Score is 23.8/100 (13th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Theaprin?

Each dot is one of Theaprin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Theaprin’s own 8.8 claims/patent is at or below the 12.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Theaprin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Theaprin's grants concentrate

Theaprin Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2016 (3 grants) versus a trough of 1 in 2018. By volume, Theaprin sits between THE Lundquist Institute FOR Biomedical Innovation AT Harbor-ucla Medical Center and Thorium Power, Inc..

THE Lundquist Ins…

9
THE Monadnock

9
THE Reynolds AND…

9
THE Surgical Inte…

9
Thermax

9
Thiele & KG

9
Thinxtream PTE

9
Thorium Power

9
Theaprin Pharmace… ◀

9

What this shows Theaprin holds 9 patents at rank #30,328, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Theaprin

By rank, the assignees closest to #30,328 in granted patent volume.

Leaders in C07C (Acyclic OR Carbocyclic Compounds)

Other assignees with the most granted patents in Theaprin's primary technology class.

Theaprin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

24 13th percentile higher than 13% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Theaprin Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	3	33.3%
2017	3	33.3%
2018	1	11.1%
2019	1	11.1%
2025partial year	1	11.1%

Which technologies does Theaprin Pharmaceuticals, Inc. patent most?

C07C - Acyclic OR Carbocyclic Compounds 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C07D - Heterocyclic Compounds 6

C07K - Peptides 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07J - Steroids 4

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Theaprin Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Theaprin Pharmaceuticals, Inc.'s lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07C
Ranked #30,402 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Theaprin Pharmaceuticals, Inc. against THE Lundquist Institute FOR Biomedical Innovation AT Harbor-ucla Medical Center, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 23.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.